Global Proteomics Services Market to Reach $16.46 Billion by 2030

Got story updates? Submit your updates here. ›

The global proteomics services market is projected to surge from $8.77 billion in 2025 to $16.46 billion by 2030, reflecting a compound annual growth rate (CAGR) of 13.4%. This robust trajectory is driven by breakthrough advances in multiplexing technologies, laboratory automation, and sophisticated bioinformatics platforms that enable unprecedented depth in protein interaction analysis, biomarker discovery, and therapeutic response prediction.

Why it matters

For pharmaceutical and biotech companies, the expansion of proteomics services offers critical capabilities to accelerate drug development, reduce R&D risk, and improve patient stratification strategies. Outsourcing complex proteomics workflows allows organizations to access cutting-edge mass spectrometry, targeted protein assays, and multi-omics integration without capital-intensive infrastructure investments.

The details

Biopharmaceutical companies are fundamentally reshaping their research models by outsourcing proteomics workflows to specialized service providers. This strategic shift allows organizations to access advanced analytical capabilities without the need for internal capital expenditures. Asia Pacific is the fastest-growing regional market, reflecting substantial capacity expansion in biopharmaceutical R&D across China, India, and Southeast Asia.

• The global proteomics services market is projected to grow from $8.77 billion in 2025 to $16.46 billion by 2030.
• In 2024, drug discovery and development applications dominated 47.0% of market share, reflecting the critical role of protein-level analysis in target identification, mechanism-of-action studies, and companion diagnostics development.
• Biopharmaceutical companies represented 40.0% of end-user demand in 2024, underscoring how proteomics services have become indispensable infrastructure for modern drug development programs.

What’s next

The market is experiencing fundamental disruption as clients transition from traditional low-throughput, single-protein assays toward integrated, high-dimensional proteomic workflows. Pharmaceutical sponsors, clinical research organizations, and academic institutions increasingly demand multiplexed panels, scalable automation, and comprehensive biomarker profiling services that deliver actionable insights across drug discovery, diagnostics, and translational research applications.